Quiz: Infection, Tumor imaging, and Therapy study quiz (4/4) (employee training


Infection, Tumor imaging, and Therapy study quiz (4/4)Online version Slides 31-42 by Joshua Liberty 1 Fluciclovine is indicated for? a Prostate cancer b Lung cancer c Melanoma d Epilepsy 2 Dose for Fluciclovine a 9 mCi b 20 mCi c 10 mCi d 12 mCi 3 What is the patient prep for a Fluciclovine study a Take potassium chloride to block thyroid uptake b Avoid significant exercise for at least one day prior c NPO at least four hours d NPO at least four hours and Avoid significant exercise for at least one day prior e Check blood sugar f NPO at least four hours and Check blood sugar 4 Fluciclovine study requires both arms down by the side. a True b False 5 How soon do we start the study and how long does it last for Fluciclovine. a 3-5 minutes; 10-20 minutes b 60 minutes; 20-30 minutes c 50 minutes; 10-15 minutes d 3-5 minutes; 5-10 minutes 6 What is the critical organ of Fluciclovine? a Pancreas b Kidneys c Bladder d Prostate e Heart f Stomach 7 What is the MOL of Fluciclovine? a Targets the CD20 antigen on surface of normal/malignant B lymphocytes b Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor positive tumors. c A synthetic amino acid transported across mammalian cell membranes by amino acid transporters d Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA 8 Which has the highest normal distribution of Fluciclovine? a Liver b Kidneys c Pancreas d Lung e Red bone marrow f Myocardium 9 Where does Fluciclovine abnormally accumulate? a Salivary glands b Small focal lesions uptake greater than blood pool c Large lesions uptake greater than or equal to bone marrow d None of these e All of these f Small focal lesions uptake greater than blood pool and Large lesions uptake greater than or equal to bone marrow 10 Fluciclovine is specific for Prostate cancer? a True b False 11 Iobengaune I-131 therapy is indicated for ? a Treatment of Castration resistant prostate cancer in adults. b Treatment of Thyroid whole body metastatic cancer c Treatment of Hyperactive Liver Mets d Treatment of adult/pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic 12 How often should a patient take inorganic iodine to block their thyroid before and after treatment? a 24 hours before; 7 days after each treatment b 24 hours before; 10 days after each treatment c 4 hours before; 10 days after each treatment d 12 hours before; 6 days after each treatment 13 Patients need to drink at least 500 mL extra fluid each day and before/after each treatment to help reduce exposure to the bladder. a True b False 14 Antimetics are drugs that reduce vomiting and nausea. a True b False 15 The dose for Iobengaune I-131 is? and what weight does it correlate with? a >50 kg; 5 to 6 mCi b <50 kg; 0.1 mCi/kg c >50 kg; 1-4 mCi d <50 kg; 0.5 mCi/kg e <50 kg; 0.1 mCi/kg, >50 kg; 5 to 6 mCi f >50 kg;1-4 mCi, <50 kg; 0.5 mCi/kg 16 What kind of image positions do we need for Iobengaune I-131. a Anterior WB b Posterior WB c Anterior and Posterior WB d Anterior and Laterals WB e Posterior and Obliques WB 17 What is the Therapy dose for Iobengaune I-131? a >62.5 kg: 500 mCi b <62.5 kg: 500 mCi c >62.5 kg: 8 mCi/kg d <62.5 kg: 8 mCi/kg e >62.5 kg: 500 mCi, <62.5 kg: 8 mCi/kg f <62.5 kg: 500 mCi, >62.5 kg: 8 mCi/kg 18 What is the main concern for patients undergoing Iobengaune I-131 therapy? a Severe and prolonged myelosuppression b Grade 4 neutropenia c Grade 4 anemia d Febrile neutropenia e All of these f None of these 19 Which of these occurs for patients undergoing Iobengaune I-131 therapy at only 5% of the receiving population. a Severe and prolonged myelosuppression b Grade 4 neutropenia c Grade 4 anemia d Febrile neutropenia e All of these f None of these 20 Piflufolastat is specific to PMSA? a True b False 21 Who is a candidate for Piflufolastat? a With suspected Metastasis who are candidates for initial therapy b With suspected recurrence based on elevated serum prostate specific antigen (PSA) level c Patients with prostate already removed from surgery. d Patients with previous history of melanoma e With suspected Metastasis who are candidates for initial therapy and With suspected recurrence based on elevated serum prostate specific antigen (PSA) level 22 What is the dose for Piflufolastat? a 20 mCi b 4 mCi c 12 mCi d 9 mCi 23 How soon can imaging with Piflufolastat can occur? a 50 minutes b 60 minutes c 20 minutes d 2 hours 24 What is the scanning region for Piflufolastat? a Skull to thigh b Top of the skull to mid thigh c Whole body d Lower abdomen to mid thigh 25 Piflufolastat can have misinterpretation in a variety of tumor types. a True b False 26 Which of these is not a adverse reaction of Piflufolastat? a Headache b Dysgeusia c Fatigue d Nausea 27 Lesions should be considered suspicious if uptake is greater than _______ for Piflufolastat? a Greater then physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. b Less then physiologic uptake in that tissue or less than adjacent background if no physiologic uptake is expected. c Greater than uptake in sites with known tumors d Greater in sites with uptake in greater concentration to surrounding tissue. 28 Tumors that do not express PSMA will still be visualized. a True b False 29 What is the MOL for Piflufolastat? a A synthetic amino acid transported across mammalian cell membranes by amino acid transporters b Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA c Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor positive tumors. d Targets the CD20 antigen on surface of normal/malignant B lymphocytes 30 Lu-177 Pluvicto is used for patients before Adrogen therapy and taxane-based chemotherapy. a True b False 31 What is the Dose for PLUVICTO? How often is it given? a 200 mCi; every 6 weeks for up to 6 doses b 300 mCi; every 6 weeks for up to 5 doses c 200 mCi; every 4 weeks for up to 5 doses d 100 mCi; every 6 weeks for up to 6 doses 32 What is needed before each dose of PLUVICTO? a PSA Levels b Complete blood counts c Whole body scan d Adequate hydration 33 If patients blood work shows inadequate RBC, WBC , and platelets, then the dose should be? a Withheld b Reduced c Permanently discontinued d Increased e Withheld, Reduced, or Permanently discontinued 34 PLUVICTO can cause severe liver toxicity. a True b False 35 MOL of PLUVICTO a Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA b Targets the CD20 antigen on surface of normal/malignant B lymphocytes c Binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC d A synthetic amino acid transported across mammalian cell membranes by amino acid transporters 36 How long should patients receiving PLUVICTO isolate from pregnant women and children? a 14 days; 7 days b 7 days; 14 days c 5 days; 10 days d 6 days; 12 days Feedback 4 Arms up 8 Liver(14%), Pancreas(3%), Lung (7%), Red bone marrow( 12%), and Myocardium (4%). 10 Not specific, it may occur in other types of cancers and benign prostatic hypertrophy in primary prostate cancer. 13 At least 2 Liters 28 They will not be visualized 30 It is used after 34 Renal Toxicity

1

Fluciclovine is indicated for?

a

Prostate cancer

b

Lung cancer

c

Melanoma

d

Epilepsy

2

Dose for Fluciclovine

a

9 mCi

b

20 mCi

c

10 mCi

d

12 mCi

3

What is the patient prep for a Fluciclovine study

a

Take potassium chloride to block thyroid uptake

b

Avoid significant exercise for at least one day prior

c

NPO at least four hours

d

NPO at least four hours and Avoid significant exercise for at least one day prior

e

Check blood sugar

f

NPO at least four hours and Check blood sugar

4

Fluciclovine study requires both arms down by the side.

a

True

b

False

5

How soon do we start the study and how long does it last for Fluciclovine.

a

3-5 minutes; 10-20 minutes

b

60 minutes; 20-30 minutes

c

50 minutes; 10-15 minutes

d

3-5 minutes; 5-10 minutes

6

What is the critical organ of Fluciclovine?

a

Pancreas

b

Kidneys

c

Bladder

d

Prostate

e

Heart

f

Stomach

7

What is the MOL of Fluciclovine?

a

Targets the CD20 antigen on surface of normal/malignant B lymphocytes

b

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor positive tumors.

c

A synthetic amino acid transported across mammalian cell membranes by amino acid transporters

d

Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA

8

Which has the highest normal distribution of Fluciclovine?

a

Liver

b

Kidneys

c

Pancreas

d

Lung

e

Red bone marrow

f

Myocardium

9

Where does Fluciclovine abnormally accumulate?

a

Salivary glands

b

Small focal lesions uptake greater than blood pool

c

Large lesions uptake greater than or equal to bone marrow

d

None of these

e

All of these

f

Small focal lesions uptake greater than blood pool and Large lesions uptake greater than or equal to bone marrow

10

Fluciclovine is specific for Prostate cancer?

a

True

b

False

11

Iobengaune I-131 therapy is indicated for ?

a

Treatment of Castration resistant prostate cancer in adults.

b

Treatment of Thyroid whole body metastatic cancer

c

Treatment of Hyperactive Liver Mets

d

Treatment of adult/pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic

12

How often should a patient take inorganic iodine to block their thyroid before and after treatment?

a

24 hours before; 7 days after each treatment

b

24 hours before; 10 days after each treatment

c

4 hours before; 10 days after each treatment

d

12 hours before; 6 days after each treatment

13

Patients need to drink at least 500 mL extra fluid each day and before/after each treatment to help reduce exposure to the bladder.

a

True

b

False

14

Antimetics are drugs that reduce vomiting and nausea.

a

True

b

False

15

The dose for Iobengaune I-131 is? and what weight does it correlate with?

a

>50 kg; 5 to 6 mCi

b

<50 kg; 0.1 mCi/kg

c

>50 kg; 1-4 mCi

d

<50 kg; 0.5 mCi/kg

e

<50 kg; 0.1 mCi/kg, >50 kg; 5 to 6 mCi

f

>50 kg;1-4 mCi, <50 kg; 0.5 mCi/kg

16

What kind of image positions do we need for Iobengaune I-131.

a

Anterior WB

b

Posterior WB

c

Anterior and Posterior WB

d

Anterior and Laterals WB

e

Posterior and Obliques WB

17

What is the Therapy dose for Iobengaune I-131?

a

>62.5 kg: 500 mCi

b

<62.5 kg: 500 mCi

c

>62.5 kg: 8 mCi/kg

d

<62.5 kg: 8 mCi/kg

e

>62.5 kg: 500 mCi, <62.5 kg: 8 mCi/kg

f

<62.5 kg: 500 mCi, >62.5 kg: 8 mCi/kg

18

What is the main concern for patients undergoing Iobengaune I-131 therapy?

a

Severe and prolonged myelosuppression

b

Grade 4 neutropenia

c

Grade 4 anemia

d

Febrile neutropenia

e

All of these

f

None of these

19

Which of these occurs for patients undergoing Iobengaune I-131 therapy at only 5% of the receiving population.

a

Severe and prolonged myelosuppression

b

Grade 4 neutropenia

c

Grade 4 anemia

d

Febrile neutropenia

e

All of these

f

None of these

20

Piflufolastat is specific to PMSA?

a

True

b

False

21

Who is a candidate for Piflufolastat?

a

With suspected Metastasis who are candidates for initial therapy

b

With suspected recurrence based on elevated serum prostate specific antigen (PSA) level

c

Patients with prostate already removed from surgery.

d

Patients with previous history of melanoma

e

With suspected Metastasis who are candidates for initial therapy and With suspected recurrence based on elevated serum prostate specific antigen (PSA) level

22

What is the dose for Piflufolastat?

a

20 mCi

b

4 mCi

c

12 mCi

d

9 mCi

23

How soon can imaging with Piflufolastat can occur?

a

50 minutes

b

60 minutes

c

20 minutes

d

2 hours

24

What is the scanning region for Piflufolastat?

a

Skull to thigh

b

Top of the skull to mid thigh

c

Whole body

d

Lower abdomen to mid thigh

25

Piflufolastat can have misinterpretation in a variety of tumor types.

a

True

b

False

26

Which of these is not a adverse reaction of Piflufolastat?

a

Headache

b

Dysgeusia

c

Fatigue

d

Nausea

27

Lesions should be considered suspicious if uptake is greater than _______ for Piflufolastat?

a

Greater then physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected.

b

Less then physiologic uptake in that tissue or less than adjacent background if no physiologic uptake is expected.

c

Greater than uptake in sites with known tumors

d

Greater in sites with uptake in greater concentration to surrounding tissue.

28

Tumors that do not express PSMA will still be visualized.

a

True

b

False

29

What is the MOL for Piflufolastat?

a

A synthetic amino acid transported across mammalian cell membranes by amino acid transporters

b

Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA

c

Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor positive tumors.

d

Targets the CD20 antigen on surface of normal/malignant B lymphocytes

30

Lu-177 Pluvicto is used for patients before Adrogen therapy and taxane-based chemotherapy.

a

True

b

False

31

What is the Dose for PLUVICTO? How often is it given?

a

200 mCi; every 6 weeks for up to 6 doses

b

300 mCi; every 6 weeks for up to 5 doses

c

200 mCi; every 4 weeks for up to 5 doses

d

100 mCi; every 6 weeks for up to 6 doses

32

What is needed before each dose of PLUVICTO?

a

PSA Levels

b

Complete blood counts

c

Whole body scan

d

Adequate hydration

33

If patients blood work shows inadequate RBC, WBC , and platelets, then the dose should be?

a

Withheld

b

Reduced

c

Permanently discontinued

d

Increased

e

Withheld, Reduced, or Permanently discontinued

34

PLUVICTO can cause severe liver toxicity.

a

True

b

False

35

MOL of PLUVICTO

a

Binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA

b

Targets the CD20 antigen on surface of normal/malignant B lymphocytes

c

Binds to PSMA, a transmembrane protein that is expressed in prostate cancer, including mCRPC

d

A synthetic amino acid transported across mammalian cell membranes by amino acid transporters

36

How long should patients receiving PLUVICTO isolate from pregnant women and children?

a

14 days; 7 days

b

7 days; 14 days

c

5 days; 10 days

d

6 days; 12 days

Feedback

4

Arms up

8

Liver(14%), Pancreas(3%), Lung (7%), Red bone marrow( 12%), and Myocardium (4%).

10

Not specific, it may occur in other types of cancers and benign prostatic hypertrophy in primary prostate cancer.

13

At least 2 Liters

28

They will not be visualized

30

It is used after

34

Renal Toxicity

Infection, Tumor imaging, and Therapy study quiz (4/4)

Quiz

Download the paper version to play

Created by

Top 10 results

Top Games

Quiz

UPS 5 Seeing Habits Quiz

Quiz

Spanish Alphabet Listening

Quiz

Photosynthesis vs Cellular Respiration - Practice Quiz

Quiz

Tissues - Practice Quiz

Quiz

Practice Quiz - Punnett Square, Variation, and Mutations